Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function
Clinical Lymphoma, Myeloma and Leukemia · Published 2026-05-25 · DOI 10.1016/j.clml.2026.05.009
Free full text
Authors (14)
Xi Chen, Shawn Hakim, Yi Ting (Kayla) Lien, Meletios A. Dimopoulos, Eben I. Lichtman, Chang-Ki Min, Wee Joo Chng, Sikander Ailawadhi, Sosana Delimpasi, Esther Hrabrick, Theodoros Papathanasiou, Sumita Roy Ghanta, Astrid McKeown, Geraldine Ferron-Brady
Abstract
PubPorta does not have an abstract for this article yet.
Read the article at the publisher →
Publication details
- Year
- 2026
Citation
Chen, X., Hakim, S., Lien, Y., et al. (2026). Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function. Clinical Lymphoma, Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.05.009
Related articles
- KMT2A-Partial Tandem Duplication associates with leukemia transformation in myelodysplastic syndrome · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
- Bispecific Antibody Therapy With Elranatamab for Refractory Waldenström Macroglobulinemia: A Case Report · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
- Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
- Treatment modalities and the impact of granulocyte colony-stimulating factor in AML patients treated with venetoclax and azacitidine: A DATAML registry study · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
- Real-World Outcomes of Melflufen Plus Dexamethasone in Heavily Pretreated Relapsed/Refractory Multiple Myeloma After Exposure to Immunotherapies · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
- SOHO State of the Art Updates and Next Questions | Predictive Markers for Ruxolitinib in Myelofibrosis · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
- SOHO State of the Art Updates and Next Questions | Best of Stem Cell Transplant: Recent Advances in Allogeneic Hematopoietic Cell Transplantation · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
- Real-World Treatment Patterns and Outcomes for Patients With Relapsed/Refractory Multiple Myeloma and Prior Exposure to Lenalidomide and Proteasome Inhibitors in the United States · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
- SOHO State of the Art Updates and Next Questions | Progress in Clonal Hematopoiesis of Indeterminate Potential/Clonal Cytopenia of Uncertain Significance · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
- SOHO State of the Art Updates and NextQuestions | Measurable Residual Disease and Its Management in Adult Acute Lymphoblastic Leukemia · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal